Sugi Predict

Sugi Predict / Compounds / SCHEMBL731455

SCHEMBL731455

SCHEMBL731455

CC(C)(C)OC(=O)N1CCOC(COS(C)(=O)=O)C1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ PDK1 Q15118 4/20 0.42
▸ EPHA2 P29317 4/20 0.41
▸ RECQL P46063 1/20 0.41
▸ ERBB2 P04626 1/20 0.40
▸ EPHB4 P54760 1/20 0.40
▸ NR1H2 P55055 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ SCN9A Q15858 1/20 0.37
▸ GPR119 Q8TDV5 1/20 0.37
▸ P2RX3 P56373 3/20 0.36
▸ P2RX2 Q9UBL9 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1439374 1.00 USP2 (0.46) USP2SMN1; SMN2PDK1EPHA2RECQL
SCHEMBL1227594 1.00 USP2 (0.46) USP2SMN1; SMN2PDK1EPHA2RECQL
SCHEMBL15416553 0.89 USP2 (0.44) USP2SMN1; SMN2PDK1EPHA2RECQL
SCHEMBL20913831 0.88 USP2 (0.43) USP2SMN1; SMN2PDK1EPHA2RECQL
SCHEMBL31712322 0.88 USP2 (0.43) USP2SMN1; SMN2PDK1EPHA2RECQL
SCHEMBL19448268 0.86 USP2 (0.43) USP2SMN1; SMN2PDK1EPHA2RECQL
SCHEMBL20913848 0.86 USP2 (0.43) USP2SMN1; SMN2PDK1EPHA2RECQL
SCHEMBL20913869 0.85 GPR119 (0.42) USP2SMN1; SMN2EPHA2RECQLNR1H2
SCHEMBL18689807 0.85 GPR119 (0.42) USP2SMN1; SMN2EPHA2RECQLNR1H2
SCHEMBL8891747 0.85 GPR119 (0.42) USP2SMN1; SMN2EPHA2RECQLNR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637451-B2 Amino quinazoline derivatives as P2X3 inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2026-05-26 — — US disclosed
US-12624043-B2 Compositions useful for treating disorders related to kit BLUEPRINT MEDICINES CORPORATION (US) 2026-05-12 — — US disclosed
EP-4288426-B1 QUINOXALINE DERIVATIVES AND USES THEREOF BLACK DIAMOND THERAPEUTICS INC (US) 2026-02-04 — — EP disclosed
US-12358886-B2 Heterocyclic compounds for use in the treatment of cancer ARTIOS PHARMA LIMITED (GB) 2025-07-15 — — US disclosed
US-20250114460-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2025-04-10 — — US disclosed
CN-114667167-B Heterocyclic compounds for the treatment of cancer 阿提奥斯医药有限公司 2024-12-20 — — CN disclosed
US-20240368181-A1 QUINOXALINE DERIVATIVES AND USES THEREOF BLACK DIAMOND THERAPEUTICS, INC. (US) 2024-11-07 — — US disclosed
US-20240317757-A1 COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT BLUEPRINT MEDICINES CORPORATION (US) 2024-09-26 — — US disclosed
EP-4384520-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND Uppthera, Inc. (KR) 2024-06-19 — — EP disclosed
US-20240051951-A1 BICYCLIC COMPOUND AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2024-02-15 — — US disclosed
EP-1939198-A1 NOVEL ADENINE COMPOUND Dainippon Sumitomo Pharma Co., Ltd. (JP) 2008-07-02 — — EP disclosed
EP-1919884-A1 N-BENZYL-MORPHOLINE DERIVATIVES AS MODULATORS OF THE CHEMOKINE RECEPTOR AstraZeneca AB (SE) 2008-05-14 — — EP disclosed
EP-1828182-A2 THERAPEUTIC PYRAZOLO[3,4-B]PYRIDINES AND INDAZOLES Warner-Lambert Company LLC (US) 2007-09-05 — — EP disclosed
US-20070043065-A1 Amide derivatives ASTRAZENECA AB (SE) 2007-02-22 — — US disclosed
WO-2007011292-A1 N-BENZYL-MORPHOLINE DERIVATIVES AS MODULATORS OF THE CHEMOKINE RECEPTOR ASTRAZENECA AB (SE) 2007-01-25 — — WO disclosed
US-20060217376-A1 Therapeutic pyrazolo[3,4-b]pyridines and indazoles WARNER-LAMBERT COMPANY LLC 2006-09-28 — — US disclosed
EP-1682520-A1 AMIDE DERIVATIVES AstraZeneca AB (SE) 2006-07-26 — — EP disclosed
WO-2006056873-A2 THERAPEUTIC PYRAZOLO[3,4-B] PYRIDINES AND INDAZOLES WARNER-LAMBERT COMPANY LLC (US) 2006-06-01 — — WO disclosed
US-20060116376-A1 Therapeutic pyrazolo[3,4-B]pyridines and indazoles WARNER-LAMBERT COMPANY LLC 2006-06-01 — — US disclosed
WO-2005042502-A1 AMIDE DERIVATIVES ASTRAZENECA AB (SE) 2005-05-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240317757-A1 COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT KIT, APC, MSH2 USP2 1513/4885SMN1; SMN2 172/4885PDK1 1664/4885
US-12624043-B2 Compositions useful for treating disorders related to kit KIT, RET, SLC26A4 USP2 2177/4885SMN1; SMN2 549/4885PDK1 1725/4885
US-20070043065-A1 Amide derivatives IL6, IL2, IL1B USP2 3576/4885SMN1; SMN2 3228/4885PDK1 1233/4885
US-20240051951-A1 BICYCLIC COMPOUND AND USE THEREOF PRMT5, PRMT6, PRMT1 USP2 2209/4885SMN1; SMN2 1957/4885PDK1 147/4885
US-20250114460-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND PLK1, BUB1B, BUB1 USP2 220/4885SMN1; SMN2 3089/4885PDK1 414/4885
US-20060116376-A1 Therapeutic pyrazolo[3,4-B]pyridines and indazoles P2RX3, P2RX4, ACHE USP2 3597/4885SMN1; SMN2 314/4885PDK1 688/4885
US-20060217376-A1 Therapeutic pyrazolo[3,4-b]pyridines and indazoles P2RX3, P2RX4, ACHE USP2 3597/4885SMN1; SMN2 314/4885PDK1 688/4885
US-12637451-B2 Amino quinazoline derivatives as P2X3 inhibitors P2RX3, P2RX1, P2RX7 USP2 3723/4885SMN1; SMN2 4574/4885PDK1 4039/4885
US-20240368181-A1 QUINOXALINE DERIVATIVES AND USES THEREOF NQO2, NQO1, GLS USP2 4301/4885SMN1; SMN2 2569/4885PDK1 196/4885
US-12358886-B2 Heterocyclic compounds for use in the treatment of cancer SDHA, DPYD, TP53 USP2 3685/4885SMN1; SMN2 2897/4885PDK1 236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.